| Titolo | Plant-derived vaccines and other therapeutics produced in contained systems |
|---|---|
| Tipo di pubblicazione | Articolo su Rivista peer-reviewed |
| Anno di Pubblicazione | 2010 |
| Autori | Franconi, Rosella, Demurtas Olivia Costantina, and Massa Silvia |
| Rivista | Expert Review of Vaccines |
| Volume | 9 |
| Paginazione | 877-892 |
| ISSN | 14760584 |
| Parole chiave | alpha interferon, biosynthesis, Biotechnology, Carrot, cell suspension, Chlamydomonas reinhardtii, Daucus carota, enzyme, Enzymes, fibronectin binding domain D2 cholera toxin B subunit fusion protein, Genetically Modified, genetics, good manufacturing practice, granulocyte macrophage colony stimulating factor, hairy root culture, hepatitis B surface antigen, human, human growth hormone, Humans, immunological adjuvant, immunology, in vitro study, interleukin 12, Lemna minor, medicinal plant, metabolism, microalga, Monoclonal antibody, Nicotiana plumbaginifolia, nonhuman, Pharmaceutical, pharmaceutics, physcomitrella patens, plant cell culture, plant growth, Plants, potato, priority journal, procedures, protein VP6, recombinant protein, Recombinant Proteins, recombinant vaccine, review, rice, soybean, Synthetic, Technology, Tobacco, Tomato, transgenic plant, unclassified drug, vaccine, vaccine production, Vaccines, virus hemagglutinin, VP1 cholera toxin B subunit fusion protein |
| Abstract | The use of contained plant systems for the production of biopharmaceuticals represents a powerful alternative to current methods, combining the benefits of whole-plant systems and cell cultures. In vitro contained production systems include plant cell suspensions, hairy root cultures, novel plants grown in contained conditions and microalgae. These systems show intrinsic advantages, such as control over growth conditions, production in compliance with good manufacturing practice and avoidance of political resistance to the release of genetically modified field crops. At present, one of the two plant-produced vaccine-related products that have gone all the way through production and regulatory hurdles derives from tobacco cell suspensions, and the second is a human therapeutic enzyme, which is expected to reach commercial development soon and derives from carrot suspension cells. In the future, several other products from contained systems are expected to reach the clinical trial stage. © 2010 Expert Reviews Ltd. |
| Note | cited By 36 |
| URL | https://www.scopus.com/inward/record.uri?eid=2-s2.0-77955248510&doi=10.1586%2ferv.10.91&partnerID=40&md5=819718156788e018e967060e9d34d5c4 |
| DOI | 10.1586/erv.10.91 |
| Citation Key | Franconi2010877 |
